The contact/kinin and complement systems in vasculitis

APMIS

Volumn 117, Issue SUPPL. 127, 2009, Pages 48-54

  Karpman, Diana ^a,b   Kahn, Robin ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Bradykinin; Complement; Contact system; Endothelium; Vasculitis

Indexed keywords

KININ; NEUTROPHIL CYTOPLASMIC ANTIBODY; KALLIKREIN;

ANCA ASSOCIATED VASCULITIS; ANTIGEN ANTIBODY COMPLEX; CLINICAL FEATURE; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SYSTEMIC LUPUS ERYTHEMATOSUS; COMPLEMENT ACTIVATION; PHYSIOLOGY; REVIEW; VASCULITIS;

COMPLEMENT ACTIVATION; HUMANS; KALLIKREINS; KININS; VASCULITIS;

EID: 66949161955     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02477.x     Document Type: Conference Paper

References (45)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001 344 : 1058 66.
2. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 2004 10 : 203 11.
3. Dauchel H, Joly P, Delpech A, Thomine E, Sauger F, Le Loet X, et al. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers. Clin Exp Immunol 1993 92 : 274 83.
4. Kawana S, Shen GH, Kobayashi Y, Nishiyama S. Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis. Arch Dermatol Res 1990 282 : 183 7.
5. Magro CM, Crowson AN, Harrist TJ. The use of antibody to C5b-9 in the subclassification of lupus erythematosus. Br J Dermatol 1996 134 : 855 62.
6. Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-Immune vasculitis. J Clin Immunol 2008. doi.
7. Fischetti F, Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006 39 : 417 28.
8. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology 1999 42 : 47 52. (Pubitemid 29322287)
9. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998 199 : 265 85.
10. Kallenberg CG. Anti-C1q autoantibodies. Autoimmun Rev 2008 7 : 612 5.
11. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004 114 : 679 88.
12. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009 20 : 289 98.
13. Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007 71 : 646 54.
14. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci 1996 93 : 8563 8.
15. Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta 2003 1639 : 169 76.
16. Vassallo G, Newton RW, Chieng SE, Haeney MR, Shabani A, Arkwright PD. Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency. Rheumatology 2007 46 : 1612 4.
17. Jönsson G, Sjöholm AG, Truedsson L, Bengtsson AA, Braconier JH, Sturfelt G. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology 2007 46 : 1133 9.
18. Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ. Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol 2007 37 : 1691 701.
19. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007 170 : 52 64. (Pubitemid 47339189)
20. Kahn R, Herwald H, Muller-Esterl W, Schmitt R, Sjogren AC, Truedsson L, et al. Contact-system activation in children with vasculitis. Lancet 2002 360 : 535 41.
21. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997 90 : 3819 43.
22. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005 57 : 27 77. (Pubitemid 40283969)
23. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 2008 20 : 55 60. (Pubitemid 351339432)
24. Shariat-Madar Z, Mahdi F, Schmaier AH. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol 2002 2 : 1841 9.
25. Yarovaya GA, Blokhina TB, Neshkova EA. Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry (Mosc) 2002 67 : 13 24.
26. Distler JH, Huber LC, Gay S, Distler O, Pisetsky DS. Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 2006 39 : 683 90.
27. Ståhl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008 111 : 5307 15.
28. Peerschke EI, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol 2008 632 : 81 91.
29. Kovacsovics T, Tschopp J, Kress A, Isliker H. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol 1985 135 : 2695 700.
30. Peerschke EI, Murphy TK, Ghebrehiwet B. Activation-dependent surface expression of gC1qR/p33 on human blood platelets. Thromb Haemost 2003 89 : 331 9.
31. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008 19 : 225 33.
32. Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 2004 10 : 179 86.
33. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998 161 : 4382 7.
34. Brogan PA, Shah V, Brachet C, Harnden A, Mant D, Klein N, et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 2004 50 : 927 36.
35. Brogan PA, Dillon MJ. Endothelial microparticles and the diagnosis of the vasculitides. Intern Med 2004 43 : 1115 9.
36. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995 155 : 1434 41.
37. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996 149 : 953 61.
38. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994 179 : 985 92.
39. van den Berg RH, Faber-Krol MC, Sim RB, Daha MR. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998 161 : 6924 30.
40. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990 265 : 3809 14.
41. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003 17 : 1003 14.
42. Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes TE, et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 2004 173 : 6921 7.
43. Bossi F, Bulla R, Tedesco F. Endothelial cells are a target of both complement and kinin system. Int Immunopharmacol 2008 8 : 143 7.
44. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992 44 : 1 80.
45. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008 180 : 1231 8.